Compare FAT & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FAT | ONCY |
|---|---|---|
| Founded | 2017 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Restaurants | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.4M | 106.1M |
| IPO Year | 2017 | 1999 |
| Metric | FAT | ONCY |
|---|---|---|
| Price | $0.48 | $0.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $10.00 | $6.00 |
| AVG Volume (30 Days) | ★ 704.1K | 688.1K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $574,143,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.05 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.36 | $0.33 |
| 52 Week High | $6.17 | $1.51 |
| Indicator | FAT | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 24.09 | 46.74 |
| Support Level | $0.46 | $0.94 |
| Resistance Level | $0.65 | $1.00 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 39.55 | 69.25 |
FAT Brands Inc is a multi-brand restaurant franchising company. It develops, markets, acquires, and manages quick service, fast casual, casual dining, and polished casual dining restaurant concepts around the world. The company operates as a franchisor of restaurants, where the company generally does not own or operate the restaurant locations but rather generates revenue by charging franchisees an initial franchise fee as well as ongoing royalties. For some of the company's brands, it also directly owns and operates restaurant locations. Its brands include Round Table Pizza, Fatburger, Johnny Rockets, Twin Peaks, and Elevation Burger among others. Geographically, the majority of the revenue for the company is generated from the United States.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.